Overview

An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepatitis B.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Collaborator:
Novartis Pharmaceuticals
Treatments:
Lamivudine
Telbivudine